Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on September 16, 2025, and filed on September 17, 2025. The Company, a foreign private issuer, executed a share repurchase through its corporate stockbroker, Merrill Lynch International, pursuant to a non-discretionary agreement entered into on June 4, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific buyback transaction rather than comprehensive financial statements. Key metrics for the September 16, 2025 transaction include:
- Shares Purchased: 210,377 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,462.00 GBp; highest price paid was 1,478.00 GBp.
- Average Price: Volume-weighted average price paid was 1,468.98 GBp.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON).
- Treasury Holdings: Following this purchase, the Company holds 247,239,100 ordinary shares in treasury.
- Shares in Issue: 4,068,163,868 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 6.08% of total voting rights.
Since the commencement of the buyback programme on June 4, 2025, the Company has purchased an aggregate of 29,104,717 ordinary shares.
Material Changes
The filing does not report material changes to revenue, profit, or operational performance. The primary change reported is the reduction in outstanding shares and the increase in treasury stock resulting from the September 16 repurchase activity.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding future operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the Company's 2024 Annual Report on Form 20-F and Q2 2025 Results.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since June 4, 2025 (reported as 29,104,717).
- Confirm the current percentage of voting rights held in treasury (reported as 6.08%).
- Review the Company's 2024 Form 20-F and Q2 2025 Results for detailed risk factors referenced in the cautionary statement.
- Check the remaining authorization or budget for the ongoing buyback programme, as this filing does not specify the total programme size or remaining capacity.